• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Cost-effectiveness considerations for managed care systems: treating depression in primary care.

作者信息

McFarland B H

机构信息

Department of Psychiatry, Oregon Health Sciences University, Portland 97201.

出版信息

Am J Med. 1994 Dec 19;97(6A):47S-57S; discussion 57S-58S. doi: 10.1016/0002-9343(94)90363-8.

DOI:10.1016/0002-9343(94)90363-8
PMID:7992827
Abstract

This article addresses the management of depression in primary care from the perspective of a health maintenance organization. The rise of managed care systems is briefly discussed with reference to their impact on choice of treatment strategies. Cost-effectiveness considerations pertinent to a health maintenance organization are reviewed. A simplified protocol for the treatment of depression with paroxetine or imipramine in the primary care sector is presented and used as an example of cost calculations. Given the assumptions used in this cost-effectiveness model, it appears that the costs of treating depression in primary care with paroxetine are approximately equal to those found with the use of imipramine. Higher acquisition costs of paroxetine are balanced by the greater labor costs associated with imipramine.

摘要

相似文献

1
Cost-effectiveness considerations for managed care systems: treating depression in primary care.
Am J Med. 1994 Dec 19;97(6A):47S-57S; discussion 57S-58S. doi: 10.1016/0002-9343(94)90363-8.
2
Cost-effectiveness of practice-initiated quality improvement for depression: results of a randomized controlled trial.实践发起的抑郁症质量改进的成本效益:一项随机对照试验的结果
JAMA. 2001 Sep 19;286(11):1325-30. doi: 10.1001/jama.286.11.1325.
3
Care for depression in a changing environment.
Health Aff (Millwood). 1995 Fall;14(3):78-89. doi: 10.1377/hlthaff.14.3.78.
4
The value of mental health care at the system level: the case of treating depression.系统层面心理健康护理的价值:以抑郁症治疗为例。
Health Aff (Millwood). 1999 Sep-Oct;18(5):71-88. doi: 10.1377/hlthaff.18.5.71.
5
Caring for depression in primary care: defining and illustrating the policy context.基层医疗中的抑郁症护理:界定并阐释政策背景。
J Clin Psychiatry. 1997;58 Suppl 1:24-7.
6
Cost-effectiveness of a collaborative care program for primary care patients with persistent depression.针对患有持续性抑郁症的初级保健患者的协作护理计划的成本效益。
Am J Psychiatry. 2001 Oct;158(10):1638-44. doi: 10.1176/appi.ajp.158.10.1638.
7
The management of depression: the implications for managed care--roundtable discussion: Part 2.
Manag Care Interface. 2000;Suppl B:19-25, 32.
8
Modelling the cost effectiveness of antidepressant treatment in primary care.初级保健中抗抑郁药治疗的成本效益建模。
Pharmacoeconomics. 1995 Dec;8(6):524-40. doi: 10.2165/00019053-199508060-00007.
9
Effects of cost-containment strategies within managed care on continuity of the relationship between patients with depression and their primary care providers.管理式医疗中的成本控制策略对抑郁症患者与其初级保健提供者之间关系连续性的影响。
Med Care. 2001 Oct;39(10):1075-85. doi: 10.1097/00005650-200110000-00005.
10
The management of depression: the implications for managed care--roundtable discussion: Part 3.
Manag Care Interface. 2000;Suppl B:26-32.

引用本文的文献

1
Formulary restriction of selective serotonin reuptake inhibitors for depression: potential pitfalls.
Pharmacoeconomics. 2001;19(10):973-82. doi: 10.2165/00019053-200119100-00001.
2
Recent care of common mental disorders in the United States : prevalence and conformance with evidence-based recommendations.美国近期常见精神障碍的护理情况:患病率及与循证建议的一致性
J Gen Intern Med. 2000 May;15(5):284-92. doi: 10.1046/j.1525-1497.2000.9908044.x.
3
Practice guidelines and late-life depression assessment in long-term care.长期护理中的实践指南与老年抑郁症评估
J Gen Intern Med. 1999 Jul;14(7):438-40. doi: 10.1046/j.1525-1497.1999.04028.x.
4
Sertraline. A pharmacoeconomic evaluation of its use in depression.舍曲林。其用于治疗抑郁症的药物经济学评价。
Pharmacoeconomics. 1996 Oct;10(4):409-31. doi: 10.2165/00019053-199610040-00009.
5
Selective serotonin reuptake inhibitors. Assessment for formulary inclusion.
Pharmacoeconomics. 1996 May;9(5):430-42. doi: 10.2165/00019053-199609050-00006.
6
The added costs of depression to medical care.抑郁症给医疗保健带来的额外成本。
Pharmacoeconomics. 1995 Apr;7(4):284-91. doi: 10.2165/00019053-199507040-00003.
7
Milnacipran. A review of its use in depression.米那普明。对其在抑郁症治疗中应用的综述。
Drugs. 1998 Sep;56(3):405-27. doi: 10.2165/00003495-199856030-00010.